Ascendis Pharma A/S vs iShares MSCI Taiwan ETF — how do they compare? Ascendis Pharma A/S trades at $254 (market cap $16.67B), while iShares MSCI Taiwan ETF trades at $105.54. The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| ASND | EWT | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $111.53 |
52-Week Low | $189.74 | $58.05 |
Enterprise Value | $17.04B | — |
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →